Posted by b2chica on May 30, 2012, at 8:38:12
1. Levomilnacipran
"I think the one that is the closest to being introduced in the United States is levomilnacipran,[2,3] which will be the fourth entry into the serotonin-norepinephrWe also saw some poster data on soon-to-be-approved antidepressants. I think the one that is the closest to being introduced in the United States is levomilnacipran,[2,3] which will be the fourth entry into the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medications. I think it's now clear that this is an effective medication. That was established for the parent drug, milnacipran, outside of the United States, but was not clearly demonstrated for milnacipran in the United States. It's only available here for treatment of fibromyalgia. Levomilnacipran has a longer half-life, and in the controlled-release formulation, it will be once-a-day dosing.
I think the thing that distinguishes this from the other members of the SNRI class is that at low therapeutic dose, the drug is much more of a norepinephrine reuptake inhibitor than a serotonin reuptake inhibitor, making it clearly different from venlafaxine, desvenlafaxine, and duloxetine."
2. 21004
We saw evidence of further proof that a novel antidepressant known as 21004,[3] which is under development by a couple of companies in a shared partnership, has measurable or real antidepressant effects and good tolerability. This medicine is not truly novel, in the sense that it does target monoamines, primarily serotonin, but is different from current available medications, in the sense that it is not a strong serotonin reuptake inhibitor. So, it is a multiaction neuromodulator from that standpoint, but it may be a useful or better-tolerated medication for patients who aren't helped by reuptake inhibitors or have too many side effects."What is madness, but nobility of soul at odds with circumstance.
The day is on Fire, and i know the purity of pure despair."
Theodore Roethke
poster:b2chica
thread:1018898
URL: http://www.dr-bob.org/babble/20120522/msgs/1018898.html